The ISSCR’s advocacy on behalf of the stem cell research community around the world, gives researchers a voice in crucial policy and regulatory debates. This valuable work benefits the members of the ISSCR and the stem cell research community and reinforces the society’s leadership representing the interests of our members globally.

The ISSCR and Japanese Society for Regenerative Medicine (JSRM) are partnering to host the virtual Tokyo International Symposium, “Stem Cells: From Basic Science to Clinical Translation,” from 27-29 October 2021. The meeting kicks off at 9:00 a.m. JST on 27 October/8:00 p.m. EDT on 26 October.

The past 20 years has seen such enormous change in stem cell science, some of which has changed our view of biology. Having attended the very first meeting of the ISSCR, the Society is like an extended family, and I feel a little like my science has grown along with the Society.

While the podcast is a fantastic extension of the journal, we are focused on publish high quality studies incorporating stem cells or their derivatives. This commitment is also reflected in our special issues, including the new one out today on organ-on-chip and microphysiological systems.

While we have this intense anticipation for stem cell products and therapies, we also have vulnerable patient populations increasingly challenged by the need to separate science from fiction. For nearly 20 years, we as ISSCR members have been the international voice of logic and moderation. As we move closer to delivery, we have an ongoing need to support this progress with appropriate ethics and research integrity.

The ISSCR is pleased to announce Keith Alm will today assume the role of CEO. He replaces retiring Nancy Witty, after 16 years of leadership.

The ISSCR is pleased to announce Melissa H. Little, PhD, Murdoch Childrens Research Institute and University of Melbourne, Australia, as president of the ISSCR Board of Directors.